Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Unfortunately for some shareholders, the Aclaris Therapeutics, Inc. (NASDAQ:ACRS) share price has dived 27% in the last thirty days, prolonging recent pain. Still, a bad month hasn't completely ruined the past year with the stock gaining 35%, which is great even in a bull market.

In spite of the heavy fall in price, given around half the companies in the United States' Pharmaceuticals industry have price-to-sales ratios (or "P/S") below 2.7x, you may still consider Aclaris Therapeutics as a stock to avoid entirely with its 10.5x P/S ratio. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so lofty.

View our latest analysis for Aclaris Therapeutics

How Has Aclaris Therapeutics Performed Recently?

Aclaris Therapeutics could be doing better as its revenue has been going backwards lately while most other companies have been seeing positive revenue growth. One possibility is that the P/S ratio is high because investors think this poor revenue performance will turn the corner. However, if this isn't the case, investors might get caught out paying too much for the stock.

Want the full picture on analyst estimates for the company? Then our free report on Aclaris Therapeutics will help you uncover what's on the horizon.

Do Revenue Forecasts Match The High P/S Ratio?

In order to justify its P/S ratio, Aclaris Therapeutics would need to produce outstanding growth that's well in excess of the industry.

Retrospectively, the last year delivered a frustrating 40% decrease to the company's top line. Even so, admirably revenue has lifted 177% in aggregate from three years ago, notwithstanding the last 12 months. Although it's been a bumpy ride, it's still fair to say the revenue growth recently has been more than adequate for the company.

Turning to the outlook, the next three years should generate growth of 16% each year as estimated by the five analysts watching the company. Meanwhile, the rest of the industry is forecast to expand by 17% per annum, which is not materially different.

With this information, we find it interesting that Aclaris Therapeutics is trading at a high P/S compared to the industry. Apparently many investors in the company are more bullish than analysts indicate and aren't willing to let go of their stock right now. Although, additional gains will be difficult to achieve as this level of revenue growth is likely to weigh down the share price eventually.

What We Can Learn From Aclaris Therapeutics' P/S?

Even after such a strong price drop, Aclaris Therapeutics' P/S still exceeds the industry median significantly. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.

Analysts are forecasting Aclaris Therapeutics' revenues to only grow on par with the rest of the industry, which has lead to the high P/S ratio being unexpected. The fact that the revenue figures aren't setting the world alight has us doubtful that the company's elevated P/S can be sustainable for the long term. Unless the company can jump ahead of the rest of the industry in the short-term, it'll be a challenge to maintain the share price at current levels.

And what about other risks? Every company has them, and we've spotted 3 warning signs for Aclaris Therapeutics (of which 2 make us uncomfortable!) you should know about.

If these risks are making you reconsider your opinion on Aclaris Therapeutics, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.